We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.1B
1-Year Est. Return 57.92%
This Fund
S&P 500
This Quarter Est. Return
+6.67%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$3.19B
AUM Growth
-$83.9M
Cap. Flow
-$366M
Cap. Flow %
-11.48%
Top 10 Hldgs %
36.17%
Holding
103
New
17
Increased
19
Reduced
13
Closed
19

Top Buys

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$71.8M
2
CNC icon
Centene
CNC
+$35.1M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$34M
4
GH icon
Guardant Health
GH
+$22.8M
5
ARNA
Arena Pharmaceuticals Inc
ARNA
+$22.5M

Top Sells

Rank Stock Value
1
PPD
PPD, Inc. Common Stock
PPD
+$41.5M
2
AZN icon
AstraZeneca
AZN
+$33M
3
PODD icon
Insulet
PODD
+$30.9M
4
GILD icon
Gilead Sciences
GILD
+$27.3M
5
ALXN
Alexion Pharmaceuticals
ALXN
+$27.2M

Sector Composition

Rank Sector Weight
1 Healthcare 91.64%
2 Financials 0.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BIIB icon
26
Biogen
BIIB
$30.9B
$45.8M 1.44%
132,272
+30,238
+30% +$9.16M
THC icon
27
Tenet Healthcare
THC
$22.2B
$44.7M 1.4%
667,073
+103,629
+18% +$6.43M
MYOV
28
DELISTED
Myovant Sciences Ltd.
MYOV
$43.5M 1.36%
1,912,188
-142,740
-7% -$3M
WAT icon
29
Waters Corp
WAT
$37.3B
$40.7M 1.27%
117,634
+4,545
+4% +$1.44M
BAX icon
30
Baxter International
BAX
$12.8B
$36.9M 1.16%
458,667
+191
+0% +$16K
SNDX icon
31
Syndax Pharmaceuticals
SNDX
$1.7B
$36.8M 1.15%
2,144,881
+660,654
+45% +$12.1M
PEN icon
32
Penumbra
PEN
$12.6B
$36.7M 1.15%
133,759
+59,408
+80% +$16.2M
AERI
33
DELISTED
Aerie Pharmaceuticals
AERI
$34.9M 1.1%
2,182,684
+115,000
+6% +$1.97M
HRTX icon
34
Heron Therapeutics
HRTX
$93.4M
$34.1M 1.07%
2,199,057
+100,479
+5% +$1.6M
CYTK icon
35
Cytokinetics
CYTK
$10.6B
$33.4M 1.05%
1,687,012
+150,639
+10% +$3.54M
MRNA icon
36
PUT
Moderna
MRNA
$21.6B
$33.1M 1.04%
+141,000
New +$25.2M
NVAX icon
37
Novavax
NVAX
$1.21B
$31.7M 0.99%
149,104
-51,641
-26% -$9.46M
ICLR icon
38
Icon
ICLR
$13.7B
$29.8M 0.93%
144,227
+78,364
+119% +$16.9M
DVAX
39
DELISTED
Dynavax Technologies
DVAX
$29.5M 0.92%
2,990,770
– –
NTLA icon
40
Intellia Therapeutics
NTLA
$1.51B
$28.9M 0.9%
178,222
-105,879
-37% -$8.24M
BFLY icon
41
Butterfly Network
BFLY
$1.86B
$26.5M 0.83%
1,828,311
– –
CANO
42
DELISTED
Cano Health, Inc.
CANO
$25.3M 0.79%
20,943
-4,323
-17% -$5.83M
ARNA
43
DELISTED
Arena Pharmaceuticals Inc
ARNA
$23.6M 0.74%
+345,523
New +$22.5M
JNCE
44
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$22.2M 0.7%
3,262,833
– –
KRTX
45
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$22M 0.69%
193,386
+14,540
+8% +$1.7M
MOH icon
46
Molina Healthcare
MOH
$10.4B
$17.7M 0.56%
70,088
– –
ZLAB icon
47
Zai Lab
ZLAB
$2.07B
$17.6M 0.55%
99,375
– –
TMO icon
48
Thermo Fisher Scientific
TMO
$214B
$17.6M 0.55%
+34,829
New +$16.4M
LH icon
49
Labcorp
LH
$25.2B
$17.6M 0.55%
+74,077
New +$16.9M
CNC icon
50
CALL
Centene
CNC
$30.5B
$16.4M 0.51%
+225,000
New +$15.4M
1
2
3 4

Similar funds

DAM
Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return
MAM
Mark Asset Management New York $1.1B AUM 43.79% 1-Year Est. Return
LCM
Legato Capital Management San Francisco, California $1.1B AUM 61.65% 1-Year Est. Return
PRS
Pinkerton Retirement Specialists Coeur D Alene, Idaho $1.1B AUM 30.57% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return
CF
Corebridge Financial Houston, Texas $1.09B AUM 1.85% 1-Year Est. Return
MIA
MMBG Investment Advisors Miami, Florida $1.09B AUM 30.96% 1-Year Est. Return

PFM Health Sciences's Q2 2021 Portfolio in Review

As of Q2 2021, PFM Health Sciences held 103 positions worth $3.19B, down 2.6% from $3.27B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

PFM Health Sciences withdrew a net $366M in Q2 2021, closing 19 positions and reducing 13 holdings. Its most notable exit was PPD, Inc. Common Stock, an estimated $41.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 82% a quarter earlier, followed by Financials.

Against the trend, PFM Health Sciences opened a new position in Seagen Inc. Common Stock worth $76.3M.

  • PFM Health Sciences's largest Q2 2021 buy was Seagen Inc. Common Stock: 482,985 shares worth $76.3M.
  • PFM Health Sciences added most to Centene in Q2 2021, an estimated $35.1M increase.
  • PFM Health Sciences's biggest Q2 2021 reduction was AstraZeneca, cutting an estimated $33M.
  • PFM Health Sciences fully exited PPD, Inc. Common Stock in Q2 2021, selling an estimated $41.5M.
  • PFM Health Sciences's ten largest holdings make up 36% of its $3.19B portfolio in Q2 2021.
  • PFM Health Sciences opened 17 new positions and closed 19 in Q2 2021.
  • PFM Health Sciences's portfolio value fell 2.6% quarter-over-quarter to $3.19B.

Based on PFM Health Sciences's 13F filing for Q2 2021, filed 16 Aug 2021.